Latham & Watkins Advises HilleVax on Pricing of Public Offering of Common Stock

HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, has announced the pricing of its public offering of 8,000,000 shares of its common stock at an initial price to the public of US$12.50 per share. All of the shares are being offered by HilleVax. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be US$100.0 million. The offering is expected to close on September 22, 2023, subject to the satisfaction of customary closing conditions. In addition, HilleVax has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of common stock at the initial price to the public, less underwriting discounts and commissions.

Latham & Watkins LLP advised HilleVax in the offering with a capital markets team led by San Diego partners Cheston Larson and Matt Bush and counsel Anthony Gostanian, with associates Rachel Staub and Shelby Harrison.